RiboTargets is first tenant for Bioincubator
Posted on 21 June 2002
RiboTargets, a structure-based drug discovery company that develops novel anti-bacterial and anti-cancer therapeutics, has begun research at its new facilities in the recently opened York Bioincubator building.
Headed by Rod Hubbard, Director of Structural Sciences for RiboTargets
and Professor of Structural Biology at the University of York, the
operation has been set up to utilise the world renowned expertise of the
University's Structural Biology Laboratory.
RiboTargets, who are headquartered in Cambridge, UK, are the first
tenant to move into the flagship incubator and have installed
specialised X-ray diffraction and computing equipment to determine
high-resolution protein structures at high throughput. Professor
Hubbard's team of specialist structural biologists demonstrated their
expertise by elucidating the crystal structures of various ligands bound
to the chaperone protein, HSP90. This research was completed within two
weeks of the team moving into the facility and forms part of
RiboTargets' portfolio of anti-cancer therapeutics programmes. The
HSP90 study is being performed in collaboration with the Institute of
Simon Sturge, RiboTargets' CEO, commented, "York has a concentration
structural biology expertise, the infrastructure and a world-class
reputation for research, that makes it the natural choice for locating
this research and development centre. The work being carried out will
accelerate our discovery activities, particularly in anti-cancer."
Notes to editors:
- RiboTargets is a privately owned pharmaceutical drug discovery
focused on the development of novel anti-bacterial and anti-cancer
therapeutics. These therapeutic areas represent significant market
- The Company has created and validated a proprietary
drug discovery engine that allows the rapid identification and
optimisation of drug candidates against both protein and nucleic acid
targets using high throughput computer-aided and experimental drug
- Over the last four years, RiboTargets has made the transition
technology platform company into a competitive drug discovery company.
RiboTargets' goal for 2002 is to make the pivotal step from research
into formal drug development. In the longer term, RiboTargets aims to
become a significant player in the anti-bacterial and anti-cancer
markets. See the website at www.ribotargets.com
- The York Bioincubator building is located on York Science Park
adjacent to the University of York. The Park was first established in
1991, and of the 22 acres set aside for development 18.5 have been
utilised, and almost 800 employees work in 31 companies on the site.
- The Structural Biology Group is an interdisciplinary group
the University's Department of Chemistry which studies protein
structure and function by a variety of techniques including molecular
biology, protein crystallography, and molecular graphics and modelling.
The laboratory is one of the best equipped in Europe, with the most
advanced crystallographic data collection, molecular graphics and
computing equipment; it is also one of the largest, with about 60
- The Group was involved in solving the structure of the
receptor, one of the crucial receptors targeted by drugs in the
treatment of a variety of women's health problems including breast
cancer and osteoporosis.